Xenon Pharmaceuticals Inc. (NASDAQ:XENE) SVP James R. Empfield purchased 10,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 15th. The shares were acquired at an average price of $2.48 per share, for a total transaction of $24,800.00. Following the completion of the purchase, the senior vice president now directly owns 10,000 shares in the company, valued at approximately $24,800. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Shares of Xenon Pharmaceuticals Inc. (NASDAQ XENE) traded up 5.36% during mid-day trading on Friday, hitting $2.95. 66,700 shares of the company were exchanged. The company has a 50 day moving average of $3.12 and a 200 day moving average of $4.89. The company’s market capitalization is $53.09 million. Xenon Pharmaceuticals Inc. has a 52 week low of $2.25 and a 52 week high of $9.95.

Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.38) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to the consensus estimate of $0.38 million. Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. Equities analysts anticipate that Xenon Pharmaceuticals Inc. will post ($0.96) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/20/xenon-pharmaceuticals-inc-xene-svp-acquires-24800-00-in-stock.html.

A number of analysts recently commented on XENE shares. Jefferies Group LLC dropped their price target on shares of Xenon Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Wednesday, June 28th. Canaccord Genuity restated a “buy” rating and set a $5.00 price target on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Zacks Investment Research upgraded shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $11.88.

Institutional investors have recently bought and sold shares of the company. KCG Holdings Inc. purchased a new position in Xenon Pharmaceuticals during the first quarter worth $122,000. Scotia Capital Inc. raised its position in Xenon Pharmaceuticals by 36.0% in the second quarter. Scotia Capital Inc. now owns 35,629 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 9,426 shares during the last quarter. Renaissance Technologies LLC raised its position in Xenon Pharmaceuticals by 18.7% in the fourth quarter. Renaissance Technologies LLC now owns 114,200 shares of the biopharmaceutical company’s stock worth $879,000 after buying an additional 18,000 shares during the last quarter. K2 Principal Fund L.P. raised its position in Xenon Pharmaceuticals by 104.4% in the first quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 59,747 shares during the last quarter. Finally, Sabby Management LLC purchased a new position in Xenon Pharmaceuticals during the first quarter worth $1,186,000. Institutional investors and hedge funds own 56.01% of the company’s stock.

Xenon Pharmaceuticals Company Profile

Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).

Insider Buying and Selling by Quarter for Xenon Pharmaceuticals (NASDAQ:XENE)

Receive News & Stock Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.